Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20705352 | 0.84 | FDPS (0.44) | FDPSNLRP3TSHRHDAC1HDAC6 | |
| SCHEMBL5225713 | 0.83 | FDPS (0.46) | FDPSNLRP3TSHRHDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL18342699 | 0.82 | FDPS (0.45) | FDPSNLRP3TSHRHDAC1HDAC6 | |
| SCHEMBL10222182 | 0.78 | FDPS (0.50) | FDPSNLRP3TSHRHDAC1HDAC6 | |
| SCHEMBL14737322 | 0.77 | FDPS (0.41) | FDPSNLRP3TSHRHDAC1HDAC6 | |
| SCHEMBL20263052 | 0.77 | NLRP3 (0.41) | FDPSNLRP3HTT | |
| SCHEMBL20263054 | 0.77 | NLRP3 (0.41) | FDPSNLRP3HTT | |
| SCHEMBL4153679 | 0.76 | FDPS (0.51) | FDPSNLRP3TSHRHDAC1HDAC6 | |
| SCHEMBL503649 | 0.76 | FDPS (0.51) | FDPSNLRP3TSHRHDAC1HDAC6 | |
| SCHEMBL9462503 | 0.76 | FDPS (0.51) | FDPSNLRP3TSHRHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233972-A1 | SUBSTITUTED HETEROCYCLES AS ANTI-INFECTIVES | ENANTA PHARMACEUTICALS, INC. | 2009-09-17 | — | — | US | disclosed |
| US-20090227600-A1 | 4-(PYRAZINE-2-YL) -PYRROLIDINE -2-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF AS HEPATITIS C VIRUS INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| CN-101087785-A | 4-Methoxymethyl-pyrrolidine-2-carboxylic acid compounds and derivatives thereof as hepatitis C virus inhibitors | GLAXO GROUP LTD (GB) | 2007-12-12 | — | — | CN | disclosed |
| US-20070270475-A1 | 4-Methoxy-Pyrrolidine-2-Carboxylic Acid Compounds and Derivatives Thereof as Hepatitis C Virus Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270475-A1 | 4-Methoxy-Pyrrolidine-2-Carboxylic Acid Compounds and Derivatives Thereof as Hepatitis C Virus Inhibitors | HAVCR2, BCKDK, ZC3HAV1L | FDPS 2009/4885NLRP3 953/4885TSHR 2531/4885 |
| US-20090227600-A1 | 4-(PYRAZINE-2-YL) -PYRROLIDINE -2-CARBOXYLIC ACID COMPOUNDS AND DERIVATIVES THEREOF AS HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, ZC3HAV1L | FDPS 3314/4885NLRP3 589/4885TSHR 1641/4885 |
| US-20090233972-A1 | SUBSTITUTED HETEROCYCLES AS ANTI-INFECTIVES | HAVCR2, EIF2AK2, HCCS | FDPS 45/4885NLRP3 2185/4885TSHR 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.